SOHO 2023 Abstract Proceedings

Abstract Proceedings

Hematology/oncology specialists from around the world gathered at the international annual meeting of the Society of Hematologic Oncology. More than 600 attendees submitted an abstract for poster presentation, oral presentation and/or publication during the event.

Poster Awards

Eight awards were presented for best posters:

FIRST PLACE
Loretta J. Nastoupil, MD
MD Anderson Cancer Center, Houston, TX, USA
IBCL-098: TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)




SECOND PLACE
Natalie Callander, MD
University of Wisconsin Carbone Cancer Ctr, Madison, WI, USA
CT-356: Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients with Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)



THIRD PLACE
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
ALL-300: First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia

• 
  HONORABLE DISTINCTION
  Faye Feller, MD
  Geron Corporation, Parsippany, NJ, USA
  MDS-572: Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/ Refractory/ Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III


• 
  HONORABLE DISTINCTION
  Harry Erba, MD, PhD
  Duke Cancer Institute, Durham, CA, USA
  AML-475: Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/ Refractory NPM1-Mutated AML


• 
  HONORABLE DISTINCTION
  Yasmin Karimi, MD
  University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
  ABCL-500: Longer follow-up reaffirms subcutaneous epcoritamab induces deep and durable complete remissions in patients with relapsed/ refractory large B-cell lymphoma: updated results from the pivotal EPCORE NHL-1 trial


• 
  HONORABLE DISTINCTION
  Naveen Pemmaraju, MD
  MD Anderson Cancer Center, Houston, TX, USA
  MPN-498: Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/ Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation and Expansion
• 
  HONORABLE DISTINCTION
  Richard F. Schlenk, MD
  Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany
  CT-186: Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia (AML) with FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial

Oral Abstract Presentations

SOHO 2023 General Sessions included a number of oral abstract presentations during the annual meeting. Abstracts considered for oral presentation were drawn from a select group of outstanding submissions. The following oral abstracts were presented during the meeting:

• ALL-300: First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia
  Elias Jabbour, MD
  MD Anderson Cancer Center, Houston, TX, USA
  


• ALL-363: Comparison of Treatment Outcomes in Adolescents and Young Adults (AYA) With Philadelphia Negative Acute Lymphoblastic Leukemia (ALL) Treated With HyperCVAD and Pediatric-Inspired Protocols (PIPs)
  Omar Shahin MBChB  
  King Hussein Cancer Center, Amman, Jordan
  


• MDS-044: Cancer Disparities in Survival of Patients With Hematologic Malignancies in the Context of Social Determinants of Health: A Systematic Review
  Marisol Miranda-Galvis, PhD
  Georgia Cancer Center, Augusta, Georgia, USA
  


• MDS-157: Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
  Guillermo Garcia-Manero, MD
  MD Anderson Cancer Center, Houston, TX, USA
  


• AML-112: Impact of Consolidation Chemotherapy Intensity Before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia
  Yosr Hicheri, MD
  Institut Paoli Clamettes, Marseille, France
  


• CML-310: Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data
  Hagop Kantarjian, MD
  MD Anderson Cancer Center, Houston, TX, USA
  


• MPN-470: Examining Racial Disparities in Primary Myelofibrosis Incidence and Survival Rates: A SEER Database Analysis from 2000‒2019
  M Bakri Hammami, MD  
  Albert Einstein College of Medicine, New York, New York, USA
  


• MM-304: Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1 
  Yi Lin, MD, PhD
  Mayo Clinic Rochester, Rochester, Minnesota, USA
  


• CLL-094: Lisocabtagene Maraleucel (liso-cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study 
  Tanya Siddiqi MD
  City of Hope Cancer Center, Duarte, California, USA
  


• IBCL-098: TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL) 
  Loretta J. Nastoupil, MD
  MD Anderson Cancer Center, Houston, Texas, USA
  


• ABCL-500: Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial 
  Yasmin Karimi, MD
  University of Michigan, Ann Arbor, Michigan, USA
  


• HL-642: Does Interim PET Assessment After Two Cycles of Treatment With Brentuximab Vedotin Still Have a Predictive Value in Hodgkin Lymphoma?  
  Ravand Samaeekia, MD, MS  
  Loma Linda University Cancer Center, Loma Linda, California, USA
  


• CT-186: Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia (AML) with FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial
  Alexander Perl, MD, MS
  University of Pennsylvania, Philadelphia, Pennsylvania, USA